LILLY & Co ELI
CIK 59478 · Director, Chairman and CEO · last filed 2023-08-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.92B
Companies
10
Total Filings
26
Lifetime Open-Market Net
$1.57B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Sigilon Therapeutics, Inc. (SGTX) Delisted | 10%+ Owner | 100 | $22.47 | $2.2K | $56.68M | 2 | 2023-08-14 |
| RNA | 10%+ Owner | 2,169,396 | $13.19 | $28.61M | $0 | 1 | 2020-06-16 |
| DERM | 10%+ Owner | 100 | $6.62 | $662 | $1.53B | 1 | 2020-02-20 |
| Elanco Animal Health Inc (ELANw) Delisted | 10%+ Owner | 0 | — | — | $0 | 1 | 2019-03-11 |
| ZYME | 10%+ Owner | 1,827,101 | $24.15 | $44.12M | -$15.35M | 14 | 2019-02-06 |
| CYPHERPUNK TECHNOLOGIES INC. (LPTX) Delisted | 10%+ Owner | — | $1.56 | — | $0 | 1 | 2018-08-13 |
| CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | 10%+ Owner | 100 | — | — | $0 | 1 | 2017-03-01 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | 10%+ Owner | 2,568,543 | $12.01 | $30.85M | $5.00M | 1 | 2016-04-14 |
| Receptos, Inc. (RCPT) Delisted | 10%+ Owner | 2,081,210 | — | — | $6.00M | 1 | 2013-11-21 |
| UTHR | 10%+ Owner | 5,251,394 | $542.66 | $2.85B | -$12.96M | 3 | 2011-07-06 |
Recent Filings · Page 3 of 3
26 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-03-01 | CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | Other (J) | +38,570,216 | $1.79B | EDGAR |
| 2016-04-14 | Spyre Therapeutics, Inc. (AGLE) Delisted | Mixed | +2,510,924 | $5.00M | EDGAR |
| 2013-11-21 | Receptos, Inc. (RCPT) Delisted | Mixed | +5,900,775 | $39.73M | EDGAR |
| 2011-07-06 | UTHR | Mixed | −860,546 | -$46.64M | EDGAR |
| 2011-07-01 | UTHR | Sell (S) | −189,734 | -$10.26M | EDGAR |
| 2010-09-13 | UTHR | Other (J) | — | $0 | EDGAR |
Showing 21–26 of 26
Prev
Page 3 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.